REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Conjugate Or Complex Of Monoclonal Or Polyclonal Antibody, Immunoglobulin, Or Fragment Thereof With Nonimmunoglobulin Material Conjugate Or Complex Of Monoclonal Or Polyclonal Antibody, Immunoglobulin, Or Fragment Thereof With Nonimmunoglobulin MaterialConjugate Or Complex Of Monoclonal Or Polyclonal Antibody, Immunoglobulin, Or Fragment Thereof With Nonimmunoglobulin Material patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178112 - Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo ... 07/05/07 - 20070154485 - Anticancer agents using verotoxin variants An attenuated verotoxin comprising a verotoxin A subunit amino acid sequence in which at least one of the amino acids at positions 167 to 172 and positions 202 to 207 from the N terminus is mutated; an attenuated verotoxin A subunit thereof; a complex of the A subunit with a ... 06/21/07 - 20070141070 - Methods and compositions for needleless delivery of antibodies The present invention relates, in part, to methods and compositions for needleless delivery of antibodies to a subject. The present invention also relates, in part, to methods for needleless delivery of fusion proteins comprising a bioactive molecule and an antibody fragment to subject. In one aspect, the methods and compositions ... 06/14/07 - 20070134258 - Gasp1: a follistatin domain containing protein The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disorders that are related to modulation of the level ... 06/14/07 - 20070134257 - Metal-binding therapeutic peptides The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes. ... 05/10/07 - 20070104724 - Attaching substances to microorganisms The invention relates to surface display of proteins on microorganisms via the targeting and anchoring of heterologous proteins to the outer surface of cells such as yeast, fungi, mammalian, plant cells, and bacteria. The invention provides a proteinaceous substance comprising a reactive group and at least one attaching peptide including ... 05/10/07 - 20070104723 - Treatment of fibrotic disease The invention relates to the use of INSP035 for treatment and/or prevention of fibrotic diseases, in particular of scleroderma. ... 04/12/07 - 20070082004 - Method for removing a proteinaceous component from a liquid-phase surfactant preparation The present invention provides a method for removing a proteinaceous component from a liquid-phase surfactant preparation comprising (a) providing a liquid-phase surfactant preparation containing a proteinaceous component; (b) adding a complexing agent to the preparation of step (a) and allowing the complexing agent to form a complex with the surfactant; ... 03/29/07 - 20070071764 - Toxin peptide therapeutic agents and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or ... 03/15/07 - 20070059316 - Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents Provided herein are conjugates, kits, articles of manufacture and methods for detection, diagnosis and treatment by photodynamic therapy of certain undesired biological substrate targets, including, but not limited to bacteria, viruses, and other pathogenic microorganisms, tumors and hyperproliferative tissue. In particular, the conjugates provided include a fluorophore or photosensitizer linked ... 02/15/07 - 20070036806 - Glp-1 analog fusion proteins The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or ... 02/08/07 - 20070031440 - Modified transferin-antibody fusion proteins Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor. ... 01/11/07 - 20070009541 - Drug conjugate composition The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that ... 01/11/07 - 20070009540 - Drug conjugate composition The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that ... 01/11/07 - 20070009539 - Drug conjugate composition The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that ... 01/11/07 - 20070009538 - Expression and export of angiogenesis inhibitors as immunofusins A homodimeric protein of the invention has angiogenesis inhibiting activity. The homodimeric protein consists of two identical fusion proteins bound together as a homodimer. Each fusion protein comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein has an angiogenesis ... 11/23/06 - 20060263375 - Antibody-serum protein hybrids Hybrid proteins are described which comprise one or more antigen-binding antibody fragments covalently linked to one or more serum carrier proteins. The hybrid proteins can bind antigens, have a long half-life in vivo and can be used in medicine for therapy and diagnosis. ... 11/16/06 - 20060257412 - Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity. ... 10/19/06 - 20060233814 - Elimination of heterogeneous or mixed cell population in tumors Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates ... 10/19/06 - 20060233813 - Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith The present invention relates to molecules that are capable of killing cells. The molecules comprise a targeting agent and a channel-forming moiety. The molecules may be polypeptides. The present invention also relates to polynucleotide sequences encoding the polypeptides of the invention. In a preferred embodiment, the channel-forming moiety comprises a ... 10/05/06 - 20060222653 - Antibodies operably linked to selected chemoattractants An antibody or fragment thereof operably linked to a one or more chemoattractants selected from the group consisting of: C5a or fragments thereof; C3a or fragments thereof; C4a or fragments thereof; and, formyl-Met-Leu-Phe (fMLP). ... 08/31/06 - 20060193868 - Functionalized nanotubes Graphitic nanotubes, which includes tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution or by adsorption of functional moieties. More specifically the invention relates to graphitic nanotubes which are uniformly or non-uniformly substituted with chemical moieties or upon which certain cyclic compounds are adsorbed and to ... 08/31/06 - 20060193867 - Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith The present invention relates to molecules that are capable of killing cells. The molecules comprise a targeting agent and a channel-forming moiety. The molecules may be polypeptides. The present invention also relates to polynucleotide sequences encoding the polypeptides of the invention. In a preferred embodiment, the channel-forming moiety comprises a ... 08/17/06 - 20060182751 - Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC or Formula XV heterocyclic-substituted 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the proliferation of tumor cells or cancer cells including ... 08/10/06 - 20060177457 - Dye-sulfenates for dual phototherapy The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are ... 07/27/06 - 20060165706 - Antibodies against ctla4 and uses therefor The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The ... 07/27/06 - 20060165705 - Immunoselective targeting agents and methods of use thereof The present invention provides immunoselective targeting agents that bind to transporters that are transiently accessible on the surface of neuronal cells, and that deliver compounds selectively to such cells. The invention provides methods of selectively killing, as well as methods of selectively promoting survival of, a neuronal cell. ... 07/20/06 - 20060159690 - H-y antigen The present invention relates to a peptide which is immunologically recognizable as a T cell epitope of the minor Histocompatibility antigen H-Y. The peptide comprises amino acid sequence SPSVDKARAEL (SEQ ID NO: 1) or FIDSYICQV (SEQ ID NO: 2). The peptide is obtainable from the minor Histocompatibility antigen H-Y. Providing ... 07/06/06 - 20060147457 - Purified composition of bispecific molecules and methods of production The invention provides a method for producing purified compositions of bispecific molecules each comprising (a) an antigen recognition portion that binds a C3b-like receptor and (b) one or more double-stranded DNA molecules cross-linked to the antigen recognition portion. In particular, the invention provides a method for purifying bispecific molecules using ... 06/22/06 - 20060134123 - Methods and means for targeted gene delivery A method for producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; and 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is ... 06/15/06 - 20060127407 - Anti-integrin immunoconjugates, methods and uses The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention ... 05/18/06 - 20060104985 - Dengue virus infection inhibitor A dengue virus infection inhibitor, as a drug effectively inhibiting the infection with dengue virus, which is characterized by containing, as the active ingredient, at least a carbohydrate molecule having as an essential constituent an oligosaccharide chain represented by the following formula (I): Hex1NAcβ1-3Hex2β1-4Hex1β1- (I) (wherein Hex1 and Hex2 represent ... 05/04/06 - 20060093611 - Method There is described a method of magnetically manipulating a cell in vivo which comprises the association of a magnetisable particle with a cell. More particularly, there is described a method of magnetically manipulating a cell which comprises the association of a magnetisable particle with a cell characterised in that the ... 04/20/06 - 20060083747 - Fc fusion The present invention relates to a simple method for generating antibody-based structures suitable for in vivo use. In particular, the invention relates to a method for the generation of antibody-based structures suitable for in vivo use comprising the steps of: (a) selecting an antibody single variable domain having an epitope ... 04/06/06 - 20060073155 - Methods and compositions for diseases associated with amyloidosis The present invention generally relates to the detection, treatment or prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compositions comprising therapeutic vaccines, antisera and molecular constructs, comprising expression vectors and fusion ... 03/30/06 - 20060067941 - Nanotubes for cancer therapy and diagnostics The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes. ... 03/23/06 - 20060062796 - Polysaccharide-polypeptide conjugate Disclosed is a method of producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide which contains at least one free amino group, wherein a polysaccharide carrier comprising vicinal hydroxyl groups is oxidized under ring opening to create vicinal aldehyde groups and is reacted with one or more base-instable ... 03/23/06 - 20060062795 - Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate Conjugates comprising a biospecific affinity counterpart and a peptide that is derived from Staphylococcal enterotoxin A, that has the ability to bind to a Vβ of a T cell receptor and has been modified at amino acid position 47, 128, 187, 225 or 227, in order to have reduced ability ... 03/09/06 - 20060051354 - Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof The present invention relates to an anti-cancer vaccine composition comprising an antigen in association with an effective amount of at least one immunomodulator chemotherapeutic adjuvant eliciting an immune response in a patient and a pharmaceutically acceptable carrier. It also relates to method of preventing tumor growth and reducing tumor growth ... 03/02/06 - 20060045881 - Anti-cancer vaccines The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, neutrophil elastase peptides other than PR1, cyclin E1 peptides, cyclin D peptides, or cyclin E2 peptides are provided. Such peptides can be used to elicit ... 02/09/06 - 20060029609 - Use of the chaperone receptor-associated protein (rap) for the delivery of therapeutic compounds to the brain and other tissues This invention provides compounds of conjugates of therapeutic or active agents with RAP or a RAP polypeptide, their pharmaceutical compositions and methods for using the such compounds and compositions in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly diseases of the central nervous system or lysosomal storage ... 02/02/06 - 20060024317 - Chemical linkers and conjugates thereof The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them. ... 02/02/06 - 20060024316 - Prostatic cancer vaccine Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof; an expression system capable of generating in situ said ... 01/26/06 - 20060018914 - Novel antibody conjugates reactive with human carcinomas The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 ... 01/26/06 - 20060018913 - Therapeutic use of anti-tf-antigen antibody The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF-Ag, or for detection of tumors or metastatic foci which express TF-Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF-Ag, the ... 01/26/06 - 20060018912 - Snares for pathogenic or infectious agents and uses related thereto The present invention provides a snare molecules comprising an attachment moiety (which facilitates attachment of a receptor to a cell) and a receptor for a toxic pathogenic or infectious agent, e.g., a virus. Methods of producing such snare molecules and their therapeutic and/or prophylactic uses are also provided by the ... 01/26/06 - 20060018911 - Design of therapeutics and therapeutics Therapeutic complexes and components of therapeutic complexes are provided herein. Also provided are methods of preparing therapeutic complexes and methods of administering therapeutic complexes. ... 01/12/06 - 20060008461 - Microparticle-drug conjugates for biological targeting This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the ... 01/05/06 - 20060002945 - Non-anaphylactogenic ige fusion proteins The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment ... 01/05/06 - 20060002944 - Treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders. ... 01/05/06 - 20060002943 - Compositions and methods for the treatment of tumor of hematopoietic origin The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. ... 01/05/06 - 20060002942 - Calicheamicin conjugates Anti-Lewis Y antibodies are described. Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. ... 01/05/06 - 20060002941 - Compositions comprising immune response altering agents and methods of use The present invention relates to immune response enhancing agents that alter an immune response generated against a heterologous target molecule. Compositions and methods of use of said immune response enhancing agents are also provided. ... 01/05/06 - 20060002940 - Method of immunotherapy Disclosed are methods and compositions for the treatment of a variety of illnesses by mimicking the outer leaflet of an apotic cell to allow for the induction of macrophage phagocytosis to serve as a means of removing unwanted and diseased cells using phosphatidylserine/cell-surface recognition domain conjugate compositions. Also disclosed are ... 12/29/05 - 20050287155 - Conjugates with reduced adverse systemic effects A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of ... 12/29/05 - 20050287154 - Autophilic antibodies and method of making and using same Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and ... 12/29/05 - 20050287153 - Serum albumin binding peptides for tumor targeting Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion. ... 12/29/05 - 20050287152 - Compositions and methods to modulate an immune response to an immunogenic therapeutic agent Methods and compositions for modulating an immune response to an immunogenic therapeutic agent are disclosed. One of the disclosed methods comprises administering an effective amount of CTLA-4 to decrease the incidence of an immune reaction in conjunction with the administration of a potentially immunogenic substance. Another method contemplates tolerizing a ... 12/29/05 - 20050287151 - Secreted protein therapeutics and uses thereof A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a ... 12/22/05 - 20050281831 - Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial ... 12/15/05 - 20050276812 - Antibody-drug conjugates and methods where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other ... 12/15/05 - 20050276811 - Natural igm antibodies and inhibitors thereof The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders. ... 12/08/05 - 20050271673 - Trifunctional reagent for conjugation to a biomolecule A reagent for conjugation to a biomolecule for diagnosis and treatment of human and animal conditions and diseases is described, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (1), a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ... 12/08/05 - 20050271672 - Cytotoxic cd44 antibody immunoconjugates The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy. ... 12/01/05 - 20050266010 - Immunotoxin (mab-ricin) for the treatment of focal movement disorders Compositions and methods for treatment of focal muscle spasms. Immunotoxin conjugates comprise a toxin conjugated to an antibody reactive to a muscle specific antigen. ... 11/24/05 - 20050260215 - Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate Methods of lysing cells associated with a disease condition, and method of treating a disease condition by lysing cells associated with the condition, by administering to a mammal a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide that is derived from Staphylococcal enterotoxin A, ... 11/24/05 - 20050260214 - Composition and method for introduction of rna interference sequences into targeted cells and tissues A composition and method are provided by which double-stranded RNA containing small interfering RNA nucleotide sequences is introduced into specific cells and tissues for the purpose of inhibiting gene expression and protein production in those cells and tissues. Intracellular introduction of the small interfering RNA nucleotide sequences is accomplished by ... 11/24/05 - 20050260213 - Fcgamma-riib-specific antibodies and methods of use thereof The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent ... 11/24/05 - 20050260212 - Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage ... 11/24/05 - 20050260211 - Compounds for intracellular delivery of therapeutic moieties to nerve cells where: B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and L is a linker coupling B ... 11/17/05 - 20050255120 - Composition and method for introduction of dna directed rna interference sequences into targeted cells and tissues Double-stranded DNA which encodes for a promoter region and for small interfering RNA nucleotide sequences is introduced into specific cells and tissues for the purpose of inhibiting gene expression and protein production in those cells and tissues. Intracellular introduction of the small interfering RNA nucleotide sequences is accomplished by the ... 11/17/05 - 20050255119 - 1,4 o-linked saccharose derivatives for stabilization of antibodies or antibody derivatives The present invention relates to compositions, preferably powdered compositions such as spray-dried or freeze-dried powders, containing an antibody or and antibody derivative and one or more 1,4 O-linked saccharose derivatives chosen from the compounds: 1,4 O-linked D-gal-saccharose (lactosucrose), 1,4 O-linked D-glu-saccharose (glucosyl sucrose) or 1,4 O-linked glu-glu-saccharose (maltosyl sucrose). Preferred ... 11/10/05 - 20050249740 - Tubulysin conjugates The invention relates to novel tubulysin conjugates (e.g. of tubulysin A) and the use thereof in the treatment of cancer diseases. ... 10/27/05 - 20050238650 - Compositions and methods for the treatment of tumor of hematopoietic origin The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. ... 10/27/05 - 20050238649 - Monomethylvaline compounds capable of conjugation to ligands Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. ... 10/20/05 - 20050232929 - Mass spectrometry of antibody conjugates wherein Ab is an antibody; D is a drug moiety; L is a linker covalently attached to Ab, and covalently attached to D; and p is 1, 2, 3, 4, 5, 6, 7, or 8; ... 10/20/05 - 20050232928 - Drug conjugates J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and Ra, Rb, R1, R2, R3, R4 are as defined in the specification. ... 10/06/05 - 20050220798 - Cancer-linked gene as target for chemotherapy Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based an their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such ... 09/29/05 - 20050214310 - Melphalan prodrugs Shown and described are the synthesis of more potent forms of C-Mel, a prodrug used in Antibody-Directed Enzyme Prodrug Therapy, that releases the clinically used anticancer alkylating agent melphalan extracellularly. Shown and described are the synthesis of a variety of melphalan analogues with the intention to promote facile intracellular drug ... 09/29/05 - 20050214309 - Methods and compositions for modulating transcription factor activity The present invention relates generally to transcription factor pathways, the modulation of such pathways, agents which modulate the activity of transcription factors, screening molecules to identify transcription factor modulators and cell or animal models for tumor-related transcription factors. More particularly, the present invention relates to the modulation of transcription factors ... 09/29/05 - 20050214308 - Treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, STIgMA, and its use in the treatment of complement-associated disorders. ... 09/29/05 - 20050214307 - Antibody conjugates for treatment of neoplastic disease Immunoconjugates of an antibody to a 240 kD melanoma tumor associated antigen were prepared. Cytotoxic immunoconjugates such as ZME-018 antibody conjugate are useful for treating proliferative cell diseases such as melanoma as well as other tumors which bear the ZME-018 antigen. Detectably labeled compositions for diagnosis of such diseases are ... 09/15/05 - 20050202028 - Binding domain-immunoglobulin fusion proteins The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC ... 09/15/05 - 20050202027 - Multivalent compounds for crosslinking receptors and uses thereof Synthetic crosslinking homobivalent and heterobivalent compounds have been designed and developed. These compounds are low in molecular weight, have antagonistic or agonistic activity, and induce the association between two identical or similar natural receptors (homobivalent compounds) or induce the association between two different natural receptors (heterobivalent compounds). ... 09/15/05 - 20050202026 - Method for producing immunoglobulins containing protection proteins and their use The immunoglobulins of the present invention are useful therapeutic immunoglobulins against mucosal pathogens such as S. mutans. The immunoglobulins contain a protection protein that protects the immunoglobulins in the mucosal environment. The invention also includes the greatly improved method of producing immunoglobulins in plants by producing the protection protein in ... 09/08/05 - 20050196402 - Ctla4-cy4 fusion proteins CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one ... 08/18/05 - 20050180983 - Antibody vaccine conjugates and uses therefor The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (βhCG) antigen linked to an anti-mannose receptor (MR) antibody. ... 08/11/05 - 20050175620 - Multivalent platform molecules comprising high molecular weight polyethylene oxide Valency platform molecules comprising high molecular weight polyethylene oxide groups are provided, as well as conjugates thereof with biologically active molecules, and methods for their preparation. The high molecular weight polyethylene oxide group has, for example, a molecular weight of greater than 22,000 Daltons, for example at least 40,000 Daltons. ... 08/11/05 - 20050175619 - Methods of producing antibody conjugates The present invention is directed to improved processes for making antibody conjugates with effector moieties, wherein the conjugation reaction is carried out in a solution comprising an alcohol. The alcohol solvated conjugation reaction may be conducted at room temperature and/or in a single-pot enclosed system that minimizes the safety risks ... 08/11/05 - 20050175618 - 5t4 ligand The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. ... 08/04/05 - 20050169933 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a ... 07/28/05 - 20050163786 - Compounds and methods for modulating adhesion molecule function Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion ... 07/14/05 - 20050152913 - Process for preapring maytansinol Processes for preparing maytansinol from disulfide-containing maytansinoid esters by reduction with LiAlH4. The maytansinol is useful for preparing cell-binding agent/maytansinoid complexes. ... 07/07/05 - 20050147618 - Clotting factor-fc chimeric proteins to treat hemophilia The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at ... 07/07/05 - 20050147617 - Compounds of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicimes wherein: P is a water soluble polymer; m is an integer of 2˜12; j is an integer of 1˜6; Ri is a group selected from H, C1-12 alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl; X and Z are linking groups; and TA is drug molecule. The conjugate has low ... 06/30/05 - 20050142141 - Delivery of enzymes to the brain Delivery of large enzymes to the brain via transport across the blood-brain barrier (BBB) utilizing conjugates, or fusion proteins, which are composed of a therapeutic enzyme and a BBB targeting agent (molecular Trojan horse). The enzyme is missing in the brain, and does not cross the BBB. The molecular Trojan ... 06/30/05 - 20050142140 - Immunoadhesin comprising a glycoprotein vi domain The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as ... 06/30/05 - 20050142139 - Cd4-igg2 formulations This invention provides formulations of the anti-HIV therapeutic, CD4-IgG2, that contain higher concentrations of the therapeutic than were previously prepared, are stable, compatible with lyophilization, and safe to administer. These formulations are suitable for intravenous, subcutaneous and intramuscular delivery, the latter two routes being potentially useful for facilitating self-administration by ... 06/23/05 - 20050136064 - Therapeutic liposome composition and method of preparation Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, ... 06/23/05 - 20050136063 - Anti-igfr antibody therapeutic combinations The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. Methods for using the combinations to treat medical conditions, such as cancer, are also provided. ... 06/23/05 - 20050136062 - Treatment of iga1 deposition diseases The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are ... 06/09/05 - 20050123549 - Ca6 antigen-specific cytotoxic conjugate and methods of using the same Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the ... 06/09/05 - 20050123548 - Modified peptides as therapeutic agents Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein ... 06/02/05 - 20050118183 - Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of said antibodies, humanized and resurfaced versions of said antibodies, functional equivalents and improved versions of said antibodies, immunoconjugates and compositions comprising said antibodies, and the uses of same in ... 06/02/05 - 20050118182 - Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 ... ### FreshPatents.com Support |